Needham Maintains Buy on Veradermics, Raises Price Target to $172

Needham analyst Serge Belanger has maintained a Buy rating on Veradermics (NYSE: MANE) and increased the price target from $164 to $172. This adjustment reflects the analyst's positive outlook on the company's performance.